Improved T Cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

The authors evaluated serial blood samples from patients with epithelial ovarian cancer undergoing standard-of-care neoadjuvant carboplatin and paclitaxel chemotherapy to characterize the evolution of the peripheral immune cell function and composition during therapy.